Point Therapeutics has released disappointing results for a Phase II study of its cancer drug. The drug did not meet the primary endpoint of six-month survival in patients with Stage III/IV pancreatic cancer. Point says it will continue to monitor patients for tumor response as well as other secondary endpoints, with final results expected in mid 2007.
"Stage IV pancreatic cancer is an extremely difficult cancer to treat, and we were pleased by the complete and partial responses seen to date in this study. We believe these responses may be clinically meaningful and intend to thoroughly evaluate all secondary endpoints before determining the clinical path forward for this indication," said Don Kiepert, President and CEO of Point Therapeutics.
- see Point's release for more